BRILIQUE® (ticagrelor)

BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with aspirin to protect patients with prior MI and a high risk* of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings†6

*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)

BRILIQUE (ticagrelor) 90mg b.d. in combination with  ASA is indicated for patients with Acute Coronary Syndromes (ACS) for up to 12 months. BRILIQUE (ticagrelor) 90mg b.d. is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment

Prescribing Information

Administration

BRILIQUE can be taken with or without food.6

BRILIQUE is indicated for use either whole, or as crushed tablets, unlike the thienopyridines.6,8,18

BRILIQUE as crushed tablets mixed in water, can be given orally or administered through a nasogastric tube into the stomach.6

BRILIQUE has two routes of administration for patients unable to swallow whole tablets
BRILIQUE has two routes of administration for patients unable to swallow whole tablets

The glass should be rinsed with a further half glass of water and the contents drunk.  It is important to flush the nasogastric tube through with water after administration of the mixture.

NG=nasogastric

Bioavailability of BRILIQUE

BRILIQUE as crushed tablets has a comparable bioavailability to whole tablets with regards to AUC and Cmax for BRILIQUE and the active metabolite. Initial exposure (0.5 and 1 hour post-dose) from crushed BRILIQUE tablets mixed in water was higher compared to whole tablets, with a generally identical concentration profile thereafter (2 to 48 hours).6

Administration of crushed 90mg tablets (orally or via nasogastric tube) resulted in higher ticagrelor plasma concentrations at early timepoints (0.5 and 1 h) vs. whole tablets.§6,21

The following graph has been adapted from the BRILIQUE SPC6

BRILIQUE has two routes of administration for patients unable to swallow whole tablets
BRILIQUE has two routes of administration for patients unable to swallow whole tablets

§36 healthy subjects were randomised in an open-label, three-period, three-treatment crossover study